TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)~* The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion~* Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Treatment with any investigational drug within 90 days prior to enrolment into the study~* Hypersensitivity to semaglutide or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide s.c. once-weekly (Type: None): Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects whose parents/guardians the investigator believes can and will comply with the requirements of the protocol~* A male or female of 9 months of age (has not attained 10 months of age) at the time of enrollment.~* Up to date on vaccinations based on ACIP recommendations and the standard practice at the investigational site.~* Written informed consent obtained from parents/guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding enrollment, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 1 month of a dose of study vaccine(s), with the exception of influenza vaccine.~* Planned administration of a tetanus toxoid (TT) containing vaccine throughout the active phase of the study (through one month after the last vaccination).~* Previous vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, C W and/or Y.~* History of meningococcal diseases.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing is required).~* A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.~* History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrollment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the active phase of the study (through one month after the last dose of study vaccine).

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 9 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Single dose GSK134612.
- Group B (Type: EXPERIMENTAL): Two doses of GSK134612.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF based on protocol-specified clinical features and at least one of the following: increased sweat chloride level, identification of 2 CF causing mutations, or demonstration of abnormal nasal epithelial ion transport.~* A 3849 + 10KB C→T or D1152H mutation on at least 1 CFTR allele.~* FEV1 ≥40% of predicted and ≤105% of predicted at screening.~Exclusion Criteria:~* A G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H mutation.~* History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.~* Ongoing or prior participation in an investigational drug study within 30 days before the Screening Visit.~* Protocol-specified abnormal laboratory values at the Screening Visit~* For subjects \<18 years of age at the Screening Visit, evidence of cataract/lens opacity determined to be clinically significant by the ophthalmologist or optometrist during the ophthalmologic examination (OE) at the Screening Visit.~* Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A, including consumption of certain herbal medications and certain fruit and fruit juices, within 14 days before Day 1.~* Pregnant, breastfeeding, or planning to become pregnant during the study.~* Sexually active subjects of reproductive potential must be willing to use appropriate contraception.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1: First Ivacaftor (IVA) Then Placebo (Type: EXPERIMENTAL): Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
- Sequence 2: First Placebo Then IVA (Type: EXPERIMENTAL): Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 and 59 months~* Weight ≥ 5 kg~* Mono-infection with P. falciparum detected by microscopy~* Parasitic density between 2,000 and 200,000 asexual forms /µL of blood~* Axillary temperature ≥ 37.5°C or history of fever during the previous 24 hours~* Ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule (home is within one hour of walk from the outpatient department, no near-term travel plans, etc.)~* Consent of a parent or guardian who is at least 18 years of age.~Exclusion Criteria:~* Presence of general danger signs as defined by the WHO,~* Presence of signs of severe malaria according to the definitions of WHO,~* Severe anemia (haemoglobin \<5 g/dL),~* Known history of symptomatic cardiac arrhythmias or with clinically relevant bradycardia,~* Family history of sudden death or of congenital prolongation of corrected QT interval,~* Use of antiarrhythmics or neuroleptics,~* Known history of hypersensitivity to any of the study medications,~* Severe malnutrition (defined as a weight-height ratio of \< -3 z-score according to the 2006 WHO reference (20) and / or a mid-upper arm circumference lower than 115 mm and / or the presence of symmetrical oedema of the feet),~* Presence of a febrile condition due to a disease other than malaria (i.e. measles, acute lower respiratory tract infection, otitis media, tonsillitis, abscess, severe diarrhoea with dehydration, etc.)~* History of a full treatment course with one of the three study drugs in the past 28 days. The prior incomplete intake of one of the three study drugs or prior intake of antimalarial drugs not being tested in the study does not exclude a patient from participating in this study. However, information on these previous treatments will be carefully recorded.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Artesunate-amodiaquine (Type: OTHER): Efficacy estimates at 95%
- Dihydroartemisinin-piperaquine (Type: OTHER): Efficacy estimates at 95%
- Artemether-lumefantrine (Type: OTHER): Efficacy estimates at 95%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants must meet 3 of the following criteria:~  * BMI ≥30 kg/m2~ * HDL Cholesterol of \<40~ * Triglycerides \>150 mg/dl~ * Fasting blood glucose \>100 mg/dl~ * Blood pressure \>130/85 mm Hg~ * Total Cholesterol of \>200 mg/dl~ * LDL Cholesterol of \>160 mg/dl~ * Interleukin 6 (IL-6) \>5pg/mL~Exclusion Criteria:~* Morbidly obese: BMI \>40 kg/m2~* Taking any cholesterol-lowering medications 30 days prior to the start of enrollment and during the course of the study.~* Enrolled in another clinical study in the past 6 months.~* Pregnant, actively infected, on medication that interfered with healing (for example, steroids), were inflicted with systemic disease such as AIDS, HIV, active hepatitis or active malignancy (clinical signs within the past 5 years), or suffered from diabetes mellitus requiring daily insulin management.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* IBS confirmed by Rome III diagnostic criteria.~* At least 18 years of age.~* Colonoscopy within the past 10 years to rule out inflammatory bowel disease; or flexible sigmoidoscopy if \< 50 years of age or previous colonoscopy \> 10 years prior.~* Willing to maintain a stable diet. including vitamins, supplements, and nutraceuticals.~Exclusion Criteria:~* Diabetes (Type 1 or 2).~* Lactose intolerance and not controlled by a lactose-free diet.~* Pregnant or planning to become pregnant or is lactating.~* History of HIV or hepatitis B or C.~* Participation in investigational study within past 30 days.~* Taking rifaximin or any other antibiotic within past 60 days.~* Unstable cardiovascular or pulmonary disease, with change in treatment in last 30 days due to worsening disease condition.~* History of GI surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin open-label (Type: EXPERIMENTAL): Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo.
- Double-blind rifaximin (retreatment) (Type: EXPERIMENTAL): Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
- Double-blind placebo (retreatment) (Type: PLACEBO_COMPARATOR): Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks \[treatment free\]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: European Active Surveillance Study (EURAS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women starting OC use or women switching OCs~* Women willing to participate in the active surveillance for several years~Exclusion Criteria:~* Women who have contraindications for OC use

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Users of Drospirenone (DRSP) (Type: None): None
- Users of Levonorgestrel (LNG) (Type: None): None
- Users of other oral contraceptives (OCs) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Prerandomization Inclusion Criteria:~* Provide written informed consent before initiation of any study related procedures.~* Be at least 18 years of age~* Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary Artery Bypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery, and/or valve replacement/repair surgery~Prerandomization Exclusion Criteria:~* Women of child-bearing potential (unless they have a negative pregnancy test)~* Recent cerebrovascular accident (within 3 months before randomization)~* Known intolerance to calcium channel blockers~* Known or suspected hypersensitivity to sodium nitroprusside~* Allergy to soybean oil or egg lecithin (components of the lipid vehicle)~* Pre-existing permanent ventricular pacing~* Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial~* Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study~Postrandomization Inclusion Criteria:~* Determined to be hypertensive perioperatively as determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clevidipine (Type: EXPERIMENTAL): Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
- sodium nitroprusside (Type: ACTIVE_COMPARATOR): Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Airway Obstruction in Infants With Lower Respiratory Infections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Group 1 Infants between 2 and 24 months that are healthy~* Group 2 Infants between 2 and 24 months that have RSV or bronchiolitis and defined as the first episode of wheezing~Exclusion Criteria:~* Group 1 and 2 - no cardiac disease, no oxygen requirement, prematurity \< 37 weeks, and cannot be in the ICU.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 2 Years
- Healthy Volunteers: t

Study Arms:
- Infants with viral lower respiratory infections (Type: OTHER): Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
- Healthy Control (Type: OTHER): Healthy infants between the ages of 2-24 month
- Bronchiolitis-Nasal wash only (Type: OTHER): Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • All patients undergoing elective laparoscopic or open colorectal resections who are eligible for IT~  * Age \>18 years~ * BMI \<40~ * Ability to understand and read English~Exclusion Criteria:~* • Not able or unwilling to sign consent.~  * Currently pregnant or lactating.~ * Patients with chronic pain, requiring daily opiate use at time of surgery.~ * Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.~ * Patients requiring emergent surgery.~ * Abdominoperineal resections~ * Any contraindications to neuraxial analgesia (coagulopathy, localized infection at the potential site of injection, pre-existing spinal canal pathology)~ * Patients with a diagnosis of inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAP block (EXPAREL) (Type: ACTIVE_COMPARATOR): After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
- Intrathecal opioid (IT) (Type: ACTIVE_COMPARATOR): single injection intrathecal hydromorphone analgesia given preoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic moderate to severe plaque type psoriasis as diagnosed by a qualified physician at least 6 months prior to baseline and with a PASI score \> 10 at baseline.~* Psoriasis patients with pruritus intensity of ≥ 30 on a 100-point VAS, with a recall period of 24h as part of the PGA-CP, both, at screening and at baseline.~Key Exclusion Criteria:~* Underlying conditions other than psoriasis which in the opinion of the investigator currently cause or influence pruritus of the skin (e.g. drug induced pruritus, renal insufficiency, diabetes).~* Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and guttate) at screening or study start.~* Ongoing use of prohibited psoriasis and non-psoriasis treatments. Washout periods have to be adhered to. If the use of any of the prohibited treatments is required, then the subject may not be included into the study.~* Pregnancy, breast feeding or inadequate contraception (if necessary)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): 300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
- Placebo (Type: PLACEBO_COMPARATOR): Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete